Print this information

Important Safety Information – HEALON5® Ophthalmic Viscoelastic Device (OVD)

Caution: Federal law restricts this device to sale by or on the order of a physician.

Indications: The HEALON5® OVD is intended for use in anterior segment ophthalmic surgical procedures of the human eye. The HEALON5® OVD is designed to create and maintain a deep anterior chamber which facilitates manipulation inside the eye with reduced trauma to the corneal endothelium and other ocular tissues. The HEALON5® OVD can also be used to efficiently separate and control ocular tissues. The HEALON5® OVD is not designed to have any pharmacological effect.

Precautions: Precautions normally considered during ophthalmic surgical procedures should be taken. Special care should be taken to ensure complete removal of the HEALON5® OVD from the entire eye including behind the lens and the chamber angles. Complete removal of the HEALON5® OVD is important to avoid intraocular pressure peaks postoperatively. Due to the greater viscosity and higher concentration of sodium hyaluronate in the HEALON5® OVD, the rise in the postoperative intraocular pressure may be higher with the HEALON5® OVD than if the same volume of other sodium hyaluronate viscoelastic products, with lower zero shear viscosity, is left in the anterior segment of the eye. Before initiating phacoemulsification, use irrigation/aspiration to create a fluid-filled space above the lens. This reduces the risk of initial visco-occlusion of the phaco tip or the irrigation line which could cause phaco tip heating. Pre-existing glaucoma, other causes of compromised outflow, higher preoperative intraocular pressure and complications in surgical procedures may also lead to increased intraocular pressure; consequently, extra care should be taken in patients with these conditions. Prophylactic pressure-lowering treatment should always be considered and especially in cases where the HEALON5® OVD has to be left in the eye for clinical reasons.

Adverse Events: Increased intraocular pressure has been reported after use of sodium hyaluronate solutions. Increased intraocular pressure is likely to occur if the HEALON5® OVD is not removed as completely as possible. Clinical judgment concerning the use of this product should be considered in cases where thorough removal may not be possible. The precautions noted above should be taken to manage any increased postoperative intraocular pressure and to reduce the likelihood of occurrence of related postoperative complications such as optic neuropathy, pupillary atonia and dilation, and iris atrophy. Rarely, postoperative inflammatory reactions (iritis, hypopyon, endophthalmitis) following the use of sodium hyaluronate, as well as incidents of corneal edema and corneal decompensation, have been reported. Their relationship to sodium hyaluronate has not been established.

Attention: Reference the Directions for Use for a complete listing of indications, warnings, and precautions.